CG Oncology, Inc. Common stock (CGON) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
CG Oncology, Inc. Common stock stock (CGON) is currently trading at $65.81. CG Oncology, Inc. Common stock PS ratio (Price-to-Sales) is 1334.24. Analyst consensus price target for CGON is $81.14. WallStSmart rates CGON as Sell.
- CGON PE ratio analysis and historical PE chart
- CGON PS ratio (Price-to-Sales) history and trend
- CGON intrinsic value — DCF, Graham Number, EPV models
- CGON stock price prediction 2025 2026 2027 2028 2029 2030
- CGON fair value vs current price
- CGON insider transactions and insider buying
- Is CGON undervalued or overvalued?
- CG Oncology, Inc. Common stock financial analysis — revenue, earnings, cash flow
- CGON Piotroski F-Score and Altman Z-Score
- CGON analyst price target and Smart Rating
CG Oncology, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
CG Oncology, Inc. Common stock (CGON) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
CG Oncology, Inc. Common stock (CGON) Key Strengths (3)
Revenue surging 409.20% year-over-year
111.28% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
CG Oncology, Inc. Common stock (CGON) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very expensive at 1334.2x annual revenue
Very expensive at 7.2x book value
Supporting Valuation Data
CG Oncology, Inc. Common stock (CGON) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 409.20%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (1334.24), Price/Book (7.16) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -21.70%, Operating Margin at -2097.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -21.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 409.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CGON Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CGON's Price-to-Sales ratio of 1334.24x trades 37% below its historical average of 2112.7x (14th percentile). The current valuation is 67% below its historical high of 4070.27x set in Feb 2026, and 11% above its historical low of 1202.55x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1916.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for CG Oncology, Inc. Common stock (CGON) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
CG Oncology, Inc. Common stock is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 4M with 409% growth year-over-year.
Key Findings
Revenue growing at 409% YoY, reaching 4M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 742% of revenue (30M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -36M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can CG Oncology, Inc. Common stock maintain 409%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact CG Oncology, Inc. Common stock.
Bottom Line
CG Oncology, Inc. Common stock is a high-conviction growth story with revenue accelerating at 409% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About CG Oncology, Inc. Common stock(CGON)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
CG Oncology, Inc. is a clinical-stage biotechnology company focused on innovating cancer therapies, with its lead asset, CG0070, being an oncolytic virus therapy designed specifically for non-muscle invasive bladder cancer. The company's strategic commitment to addressing significant unmet needs in oncology emphasizes its potential impact on patient outcomes and treatment paradigms. As CG Oncology progresses through clinical trials and approaches key regulatory milestones, it leverages its proprietary platform to position itself favorably in the competitive oncology landscape. This strategic focus on pioneering therapeutic solutions presents a compelling opportunity for institutional investors seeking to invest in transformative advancements in cancer care.